JLE

Innovations & Thérapeutiques en Oncologie

MENU

onCOGITE: The fight against cognitive disorders post-oncological treatment Volume 8, issue 1, January-February 2022

Figures


  • Figure 1
Authors
1 CRLCC
Institut Bergonié
229, cours de l’Argonne
33076 Bordeaux cedex
France
2 Association onCOGITE,
reconnue d’intérêt général
90, rue de Saint-Genès
33000 Bordeaux
France
3 Laboratoire de psychologie, EA4139
3, ter place de la Victoire (bât. H)
33076 Bordeaux cedex
France
4 AFSO
76, rue Marcel-Sembat
33130 Bègles
France
5 Centre hospitalier Dubois-Brive
3, boulevard Dr-Verlhac
19100 Brive-la-Gaillarde
France
* Tirés à part

Cognitive impairment is frequently reported in cancer patients and there is currently no standardized universal treatment for this condition. The presented study is an exploratory investigation to evaluate the effects of a cognitive remediation programme (ONCOGITE) on a group of cancer patients. Twenty-nine patients with this disease were recruited, of whom 96.6% were women being followed for localized breast cancer or lymphoma, as first intention-to-treat. From the initial assessment until the fifth month, results showed an overall positive impact of the remediation programme on the patients. In terms of quality of life, we found an improvement on the subscale of cognitive functioning and global health (QLQ-C30 version 3). A significant improvement was also observed in the scores related to anxiety-depressive symptomatology (HADS), as well as for the results concerning cognitive complaints (FACT-COG French version 3) based on the perceived cognitive impairment subscale, quality of life and perceived cognitive skills. In terms of fatigue (Piper's Echelle de Fatigue), we found a significant improvement in the “cognitive mood” subscale. Finally, a significant improvement was found in motivation to return to work and in confidence in physical and intellectual conditions. The results suggest that the proposed intervention is beneficial for the management of cancer-related cognitive symptomatology and the data should be confirmed in a larger-scale randomized trial.